About EBGLYSS®
EBGLYSS®
EBGLYSS® is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents (≥12 years of age and with a body weight of at least 40 kg) who are candidates for systemic therapy.1
How to use EBGLYSS®
In a 250 mg solution for injection in a pre-filled pen
In a 250 mg solution for injection in a pre-filled syringe
Scientific Resources
Clinical Trials
We invite you to read the results of two phase III monotherapy trials aimed at evaluating the efficacy and safety of EBGLYSS® in monotherapy: ADvocate 1 and ADvocate 2.
Clinical Trials
We invite you to read the results of two phase III monotherapy trials aimed at evaluating the efficacy and safety of EBGLYSS® in monotherapy: ADvocate 1 and ADvocate 2.
Clinical Trials
We invite you to read the results of two phase III monotherapy trials aimed at evaluating the efficacy and safety of EBGLYSS® in monotherapy: ADvocate 1 and ADvocate 2.
Patient support
▼ This medicinal product is subject to additional monitoring.
HQ-EBG-2400007
FOOTNOTES
†After a 16-week Q2W induction period or once clinical response is achieved, the recommended maintenance dose of EBGLYSS® is 250 mg every four weeks.1
**Significant improvements in Pruritus NRS from baseline occurred as early as day 2 for ADvocate 1.5
REFERENCES
1. EBGLYSS® (lebrikizumab). EU Summary of Product Characteristics.
2. Gonçalves F, et al. Drugs Context. 2021 Mar 30;10:2021-1-7.
3. Bieber T. Allergy. 2020;75:54-62.
4. Tsoi LC, et al. J Invest Dermatol. 2019 Jul;139(7):1480-1489.
5. Yosipovitch G, et al. Br J Dermatol. 2024 Jan 23;190(2):289-291.
6. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080–1091.
7. Blauvelt A, et al. Br J Dermatol. 2023 May 24;188(6):740–748.
8. Thaçi D, et al. Efficacy and Safety of Lebrikizumab Is Maintained Up to 3 Years in Patients With Moderate-to-Severe Atopic Dermatitis: ADvocate 1 and ADvocate 2 to ADjoin Long-Term Extension Trial. Presented at the European Academy of Dermatology and Venereology (EADV) ; Amsterdam, Netherlands; September 25-28, 2024 . D1T01.2.